Haisco Pharmaceutical Group Co. Ltd. has divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of inflammatory, renal, psychiatric, cardiovascular, eye, respiratory and metabolic disorders, as well as cancer.
Glutathione transferase omega-1 (GSTO1-1) helps drive inflammatory disorders and cancers by activating the NLRP3 inflammasome and promoting production of pro-inflammatory interleukin-1b. Numerous small molecules have been generated to inhibit the enzyme, but none has progressed to clinical trials, mostly because of off-target activity or poor pharmacokinetics.
Carbon Biosciences Inc. has presented data on a parvovirus-based vector that restores full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene for treating cystic fibrosis.
Prelude Therapeutics Inc. has outlined its plans to prioritize programs within its pipeline and announced an exclusive option agreement with Incyte Corp.
Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors.
Boehringer Ingelheim Pharma GmbH & Co KG and CDR-Life Inc. have entered into a new global licensing agreement to develop CDR-111 for autoimmune diseases.
Advanced gastric cancer continues to pose a significant medical challenge because of the scarcity of effective treatments and the frequent development of resistance to available drugs.
RSS
